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e-Prescribing Mandate
In 2018, the Massachusetts Legislature issued a mandate 
that all controlled substance (CS) and device prescriptions be 
issued electronically as of January 1, 2020. Changes to the 
regulations were made to implement this mandate based on 
public comments and other states’ experiences when imple-
menting their own e-prescribing requirements. Although the 
changes took effect on January 1, 2020, the regulation includes 
a one-year grace period before e-prescribing will be required. 
This will give prescribers, facilities, and pharmacists more 
time to fully transition to e-prescribing.
Starting January 1, 2021, all prescriptions for federally 
scheduled CS and medical devices must be issued on 
federally compliant e-prescribing systems. However, 
there are several exceptions to the e-prescribing requirement, 
including prescriptions issued in emergency situations, 
prescriptions for Schedule VI medications (non-federally 
scheduled CS), prescriptions for residents of nursing homes 
(mandate delayed through January 1, 2023), and other 
exceptions as stated in the revised 105 Code of  Massachusetts 
Regulations (CMR) 721.070. Time-limited waivers are also 
available.
Waiver requests may be submitted to the Drug Control 
Program at any time after January 1, 2020, but should be 
submitted by October 1, 2020, to ensure processing and 
approval of the request by January 1, 2021. 
If a prescriber chooses to e-prescribe a Schedule VI 
medication and the prescription fails to transmit properly, 
resulting in a computer-generated fax, a pharmacist may 
dispense the medication as if it were a valid oral prescription.
At any time, a pharmacist receiving an otherwise valid 
written or oral prescription may dispense the prescription 
without having to verify that a waiver has been granted 
to the prescriber or that an exception applies.
For more information on e-prescribing, prescription format 
and security, and these regulatory changes, please contact the 
Drug Control Program and view 105 CMR 721 (choose “Post-
Comment Regulation” to show changes effective in 2020).
USP Chapter <800> in Community 
Pharmacies
Massachusetts regulations require pharmacists to 
follow all current chapters of United States Pharmacopeia 
(USP), including USP General Chapter <800> Hazardous 
Drugs—Handling in Healthcare Settings. Even though most 
community pharmacies typically only dispense hazardous 
drugs (HDs) in their final dosage form, they are also required 
to follow those standards. The Massachusetts Board of 
Registration in Pharmacy has recently approved an advisory to 
aid retail pharmacies with compliance of USP Chapter <800>.
All the containment strategies of  USP Chapter <800> must 
be followed in these three situations:
1. when manipulating antineoplastic drugs;
2. when compounding with any National Institute 
for Occupational Safety and Health HD active 
pharmaceutical ingredient (API), including crushing 
tablets or opening capsules of an HD; or
3. if an assessment of risk has not been performed.
As an example, if clonazepam tablets are crushed to 
compound a suspension, this would be considered nonsterile 
HD compounding with a hazardous API and subject to 
the containment requirements of USP Chapter <800>. 
Containment would include using a powder hood that is 
located in a negative pressure room.
Each entity must have a designated person to develop and 
implement procedures, monitor for compliance, and meet 
other requirements of USP Chapter <800>. This person does 
not have to be a pharmacist or pharmacy technician, and does 
not have to be in the pharmacy.
An HD program must be developed to address all appli-
cable requirements of USP Chapter <800> including at least 
the following:
 ♦ identify all HDs and the risk category of each one, make 
an assessment of risk, and address scenarios where per-
sonal protective equipment may be needed; 
 ♦ develop standardized storage and handling procedures; 
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nizations) to make sure there is a reliable supply of 
medically important drugs.
In addition to these recommendations, the report outlines 
the agency’s ongoing initiatives to mitigate drug shortages 
and legislative proposals in President Donald J. Trump’s 
Fiscal Year 2020 budget. FDA also highlighted the need 
for international action, including global implementation of 
the International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use’s (ICH’s) 
ICH Guideline Q12: Technical and Regulatory Consider-
ation for Pharmaceutical Product Lifecycle Management, 
which provides opportunities for regulatory flexibility in 
making post-approval changes to the product or its manu-
facturing process.
“We hope that the recommendations set forth in this report 
will help to set a framework that all stakeholders can assess 
and implement as we work together to further mitigate the 
public health impact that drug shortages have on American 
consumers,” FDA stated. “In the meantime, the FDA’s em-
ployees remain committed to working behind-the-scenes to 
anticipate and help mitigate shortages and make sure that 
patients have access to the drugs they need.” 




HHS Announces Guide for Appropriate 
Tapering or Discontinuation of Long-
Term Opioid Use 
The United States Department of Health and Human 
Services (HHS) has published a new guide for clinicians 
intended to provide guidelines for tapering or discontinu-
ing long-term opioid use. The guide, titled HHS Guide for 
Clinicians on the Appropriate Dosage Reduction or Discon-
tinuation of Long-Term Opioid Analgesics, covers impor-
tant issues to consider when changing a patient’s chronic 
pain therapy. The guide also lists issues to consider prior 
to making a change, when initiating the change, and as a 
patient’s dosage is being tapered, including the need to treat 
symptoms of opioid withdrawal and provide behavioral 
health support.
“Care must be a patient-centered experience. We need to 
treat people with compassion, and emphasize personalized 
care tailored to the specific circumstances and unique needs 
Page 2
DEA Proposes New Regulations to 
Address Opioid Epidemic
Drug Enforcement Administration (DEA) has announced 
proposed regulations to improve the agency’s ability to 
oversee the production of opioids and other potentially 
dangerous drugs. The proposed regulation would further 
limit the quantities of medications that might be vulnerable 
to diversion and misuse. The proposal would also amend the 
manner in which DEA grants quotas to certain registered 
manufacturers to levels aligned with current manufactur-
ing standards aimed at promoting quality and efficiency 
while also ensuring the country has sufficient quantities of 
Schedule II controlled substances (CS) necessary for medi-
cal, scientific, research, and industrial needs.
The proposal introduces several new types of quotas that 
DEA would grant to certain DEA-registered manufactur-
ers. These use-specific quotas include quantities of CS for 
use in commercial sales, product development, packaging/
repackaging and labeling/relabeling, or replacement for 
quantities destroyed. These quotas are intended to improve 
DEA’s ability to respond quickly to drug shortages.
The proposed changes build on 2018 regulatory 
changes that gave a role to state attorney generals and 
other federal agencies in setting the aggregate produc-
tion quotas for Schedule I and II CS. The proposed 
regulations are available in the October 23, 2019, Fed-
eral Register announcement at https://www.federalregister 
.gov/documents/2019/10/23/2019-21989/management-of-
quotas-for-controlled-substances-and-list-i-chemicals. 
FDA Issues Report on Root Causes and 
Solutions to Drug Shortages
Food and Drug Administration (FDA) has released a 
new report, Drug Shortages: Root Causes and Potential 
Solutions, which identifies root causes for drug shortages 
and recommends three “enduring solutions” to address the 
shortages. These recommendations include:
♦ creating a shared understanding of the impact of drug
shortages on patients and the contracting practices that
may contribute to shortages;
♦ developing a rating system to incentivize drug manu-
facturers to invest in quality management maturity for
their facilities; and
♦ promoting sustainable private sector contracts (eg,
with payers, purchasers, and group purchasing orga-
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of each patient,” said ADM Brett P. Giroir, MD, assistant 
secretary for health in a press release. “This Guide provides 
more resources for clinicians to best help patients achieve 
the dual goals of effective pain management and reduction 
in the risk for addiction.” 
FDA Releases Draft Best Practice 
Document for Postmarket Drug 
Surveillance
As part of FDA’s efforts to enhance the efficiency of its 
postmarket drug safety surveillance, the agency has released 
a new best practices document, Best Practices in Drug and 
Biological Product Postmarket Safety Surveillance for FDA 
Staff. The draft document outlines FDA’s approach for time-
ly postmarket analyses of drugs and biologics, and includes 
a high-level overview of tools, methods, and signal detection 
and evaluation activities, using varied data sources, for drug 
safety. The goal is to provide a broader context and a general 
overview of ongoing efforts and commitments.
“Our best practices document incorporates the guiding 
principle that postmarket safety surveillance is a dynamic 
and constantly evolving field,” FDA said in a statement 
announcing the document’s release. “By using a risk-based 
approach, the FDA takes into account the nature of the drug, 
its potential adverse events, the intended population, and 
the potential for serious outcomes, as well as the impact on 
individuals and the overall potential impact on the health 
of the public.”
The full draft document can be accessed at https://www 
.fda.gov/media/130216/download.
FDA Issues Revised Draft Guidance on 
Regulation of Homeopathic Products, 
Withdraws 1988 Compliance Policy Guide
FDA is taking two new steps to clarifying their approach 
to regulating drug products labeled as homeopathic: re-
vising draft guidance previously published in 2017, and 
withdrawing the Compliance Policy Guide (CPG) 400.400 
issued in 1988. These moves were announced in a statement 
published on the FDA website. Homeopathic products are 
often marketed as natural alternatives to approved prescrip-
tion and nonprescription products and are widely available 
in the marketplace. Homeopathic products, however, are 
marketed without FDA review and may not meet modern 
standards for safety, effectivity, quality, and labeling. FDA 
uses a risk-based approach to monitor these products and 
to evaluate reports of adverse events.
The revisions to the 2017 draft guidance provide further 
information about FDA’s approach. The guidance details a 
risk-based enforcement policy prioritizing certain catego-
ries of homeopathic products that could pose a higher risk 
to public health. These include products with particular 
ingredients and routes of administration, products for vul-
nerable populations, and products with significant quality 
issues. FDA has invited public comment on the guidance 
before it is finalized. The full guidance and instructions for 
providing comment are available in the Federal Register 
announcement.
CPG 400.400, Conditions Under which Homeopathic 
Drugs May be Marketed, is being withdrawn due to incon-
sistency with the agency’s risk-based approach to regulatory 
and enforcement action and is therefore being withdrawn. 
Specifically, FDA states that it has encountered multiple 
issues with homeopathic drug products posing significant 
risk to patients, even though the products, as labeled, ap-
peared to meet the conditions of CPG 400.400.
DEA Warns of Increase in Scam Calls 
Targeting Pharmacists and Other DEA-
Registered Providers
DEA is warning health care providers and other members 
of the public of another increase in fraudulent phone calls 
attempting to extort money. Though the tactics change regu-
larly, the callers typically claim to represent DEA and pro-
vide either fake names and badge numbers, or the names of 
well-known senior officials with DEA. The scammers then 
threaten legal action, including arrest, against the victim 
unless large fines are paid by wire transfer. Most recently, 
the scammers appear to be spoofing a DEA number based 
out of Salt Lake City, UT, according to a DEA press release.
The agency emphasizes that DEA will never contact 
practitioners by phone to demand money or any form of 
payment. DEA will not request any personal or sensitive 
information by phone, and notification of a legitimate 
investigation or legal action is always made via official 
letter or in person.
DEA asks anyone who receives a call from a person pur-
porting to be a DEA special agent or other law enforcement 
official asking for money to refuse the demand and report 
the threat using the online form or by calling 877/792-2873. 
Reporting these calls will assist DEA in investigating and 
stopping this activity.
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 ♦ make sure all personnel are appropriately trained for 
their specific job function; and
 ♦ develop comprehensive policies and procedures 
to include situations such as spills, deactivation, 
decontamination, cleaning, and waste.
Veterinary Prescription Pearls
Most veterinary medications are dosed by weight, similar 
to pediatric medicine, and may seem significantly higher or 
lower than a typical human dose. For instance, since dogs 
metabolize levothyroxine very quickly, doses are usually 
quite high and are therefore dosed in mg not mcg.
Human over-the-counter (OTC) drugs are not labeled 
for use in any species other than humans. Consequently, 
pharmacists are prohibited by federal law to recommend a 
human OTC drug for an animal unless such use is pursuant 
to a prescription or documentation from a veterinarian. 
Veterinarians do not have National Provider Identifier 
numbers because they do not provide care to humans. 
Their prescriptions require their Massachusetts Controlled 
Substances Registration number for Schedule VI and Drug 
Enforcement Administration (DEA) number for Schedules 
II through V. 
Food and Drug Administration’s (FDA’s) “Green Book” 
contains a listing of FDA-approved drugs for animals, 
most of which are sold by veterinary distributors who limit 
distribution only to veterinarians.
Pharmacists who fill veterinary prescriptions should 
have access to at least one veterinary drug reference (eg, 
Plumb’s Veterinary Drugs). References will contain valuable 
information such as:
 ♦ xylitol, which is found in commercial gabapentin 50 mg/
ml, is toxic to dogs 
 ♦ since cats do not absorb or convert prednisone to 
prednisolone very well, prednisolone is preferred over 
prednisone
 ♦ any amount of acetaminophen is toxic to cats
As a reminder, there are no requirements for veterinarians 
in Massachusetts to review the Massachusetts Prescription 
Awareness Tool prior to issuing prescriptions. Monitor vet-
erinary prescriptions for federally controlled drugs for any 
potential substance misuse issues.
Getting to Know Your Board Members – 
Susan Cornacchio
This quarter, the Board is highlighting member Susan 
Cornacchio.
As a public member of the Board, Susan Cornacchio 
began her career as a critical care nurse and later became an 
attorney to practice as court-appointed counsel for indigent 
criminal defendants. 
Susan eventually transitioned to a role at the Board of 
Registration in Medicine, to direct the monitoring program 
for physician compliance with substance abuse and mental 
health monitoring contracts. She conferred with physicians 
and counsel with the goal of helping physicians in their 
recovery, while keeping patients in the commonwealth safe.
From there, she began the patient safety and risk 
management part of her career and was responsible for 
reducing errors, improving the quality of patient care, and 
reducing malpractice risk in a wide variety of clinical and 
corporate settings across the greater Boston, MA, area. 
With her current organization, she continues to promote 
patient safety in a transformative health care setting on a 
national scale. 
Susan feels that as the health care landscape changes and 
the role of the pharmacist expands over the next several 
years, health care regulators will need to keep pace. They will 
need to protect the public by quickly identifying emerging 
pharmacy practice risks, while also supporting the profession 
as it evolves. 
Susan advises pharmacists to “fully participate in the 
pharmacy community as possible, by attending conferences, 
educational programs, and attending board meetings. Expo-
sure to pharmacists from a wide variety of practice settings 
will broaden their perspective and ability to adapt to the ever-
changing world of pharmacy.”
Did You Know?
The Board’s policy on the use of automated dispensing 
devices (ADD) requires retail pharmacies that have placed 
an ADD in an authorized facility for dispensing routine 
medications to obtain a machine-specific DEA number and 
CS registration.
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